SCHEMBL6656423

SCHEMBL6656423

C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 7/20 0.49
▸ REN P00797 4/20 0.49
▸ DPP4 P27487 3/20 0.48
▸ FAP Q12884 2/20 0.48
▸ DPP7 Q9UHL4 2/20 0.48
▸ PREP P48147 1/20 0.48
▸ DPP8 Q6V1X1 1/20 0.48
▸ DPP9 Q86TI2 1/20 0.48
▸ XIAP P98170 1/20 0.47
▸ F2 P00734 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ LTA4H P09960 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ PEPD P12955 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ PTGS1 P23219 1/20 0.46
▸ HTR2A P28223 1/20 0.46
▸ PTGS2 P35354 1/20 0.46
▸ HRH1 P35367 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16620343 1.00 ACE (0.49) ACERENDPP4FAPDPP7
SCHEMBL29692517 0.89 DPP4 (0.50) ACERENDPP4FAPDPP7
SCHEMBL5178008 0.89 DPP4 (0.48) ACERENDPP4FAPDPP7
SCHEMBL30661441 0.87 XIAP (0.47) ACERENDPP4FAPDPP7
SCHEMBL30661450 0.87 XIAP (0.47) ACERENDPP4FAPDPP7
SCHEMBL29689488 0.87 DPP4 (0.54) ACERENDPP4DPP7DPP8
SCHEMBL29589367 0.86 DPP4 (0.55) ACERENDPP4FAPDPP7
SCHEMBL22811041 0.85 DPP4 (0.45) ACERENDPP4FAPDPP7
SCHEMBL30775497 0.85 DPP4 (0.56) ACERENDPP4FAPDPP7
SCHEMBL29615359 0.85 ACE (0.43) ACERENDPP4FAPDPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071525-A PD-L1 binding molecules and uses thereof 广东菲鹏制药股份有限公司 2026-05-22 — — CN claimed
CN-122071526-A PVRIG binding molecules and uses thereof 广东菲鹏制药股份有限公司 2026-05-22 — — CN claimed
US-20260048156-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2026-02-19 — — US claimed
EP-4452326-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2024-10-30 — — EP claimed
CN-118834265-A Polypeptide with complement inhibition activity, fusion protein and medical application thereof 北京拓界生物医药科技有限公司 2024-10-25 — — CN claimed
CN-118541171-A FAP-targeted pharmaceutical products for cancer treatment and diagnosis 原子治疗有限公司 2024-08-23 — — CN claimed
US-20240083999-A1 VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2024-03-14 — — US claimed
EP-4334349-A2 VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF Trustees Of Tufts College (US) 2024-03-13 — — EP claimed
CN-117624349-A Humanized design and expression verification of murine HA tag antibody 浙江大学绍兴研究院 2024-03-01 — — CN claimed
US-20230374112-A1 Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof BDC CAPITAL INC. (CA) 2023-11-23 — — US claimed
CN-116621983-A anti-ROBO 1 humanized antibodies, antigen binding fragments thereof and uses thereof 四川阿思科力生物科技有限公司 2023-08-22 — — CN claimed
CN-116622775-A Cell for fixed-point knocking in hROBO1CAR, preparation method and application 四川阿思科力生物科技有限公司 2023-08-22 — — CN claimed
WO-2023118195-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2023-06-29 — — WO claimed
WO-2022235645-A2 VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF TRUSTEES OF TUFTS COLLEGE (US) 2022-11-10 — — WO claimed
WO-2022067445-A1 BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF CORPORATION GENACOL CANADA INC. (CA) 2022-04-07 — — WO claimed
US-12637499-B2 Adrenomedullin analog, method for producing the same, and pharmaceutical use thereof UNIVERSITY OF MIYAZAKI (JP) 2026-05-26 — — US disclosed
CN-122071525-A PD-L1 binding molecules and uses thereof 广东菲鹏制药股份有限公司 2026-05-22 — — CN disclosed
EP-1436317-A1 MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF TRIPEP AB (SE) 2004-07-14 — — EP disclosed
WO-2003024995-A1 MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF TRIPEP AB (SE) 2003-03-27 — — WO disclosed
US-5849525-A Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 1998-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048156-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS FAP, ALK, FIBP ACE 680/4885REN 1363/4885DPP4 650/4885
US-12637499-B2 Adrenomedullin analog, method for producing the same, and pharmaceutical use thereof NPR3, VIP, IAPP ACE 836/4885REN 315/4885DPP4 925/4885
US-20240083999-A1 VHH POLYPEPTIDES THAT BIND TO INTERLEUKIN 6 (IL-6), COMPOSITIONS AND METHODS OF USE THEREOF IL6, IL6ST, CXCR6 ACE 2024/4885REN 969/4885DPP4 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback